U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Shares of Novo Nordisk A/S (NVO) climbed 0.4% on Monday and rose in extended trading after the Danish drugmaker said it had ...

Novo Nordisk (NVO) asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this ...

Obesity alters how medications work, increasing the risk of underdosing, overdosing, and unknown interactions. Are package ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Federal health officials suggest the additives are contributing to rising rates of diabetes, obesity and ADHD in children.

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that ...

U.S. FDA Commissioner Marty Makary said on Tuesday that the agency plans to remove petroleum-based synthetic food dyes from ...

The FDA and HHS will phase out eight synthetic food dyes by 2026, citing health risks such as ADHD and obesity. The move ...

The FDA announces a plan to phase out petroleum-based synthetic dyes from the U.S. food supply to improve children's health.